Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Entheon Biomedical Corp. (C:ENBI)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for ENBI within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 11, 2022 08:30 ET
Entheon Announces Closing of Previously Announced Sale of Certain DMT Clinical Assets
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that, further to its news release dated June 7, 2022, it has completed the sale of its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. pursuant to an asset purchase agreement for a purchase price of CAD$1,000,000 (the "Transaction"). In connection with the Transaction, the Purchaser has assumed all accrued liabilities and accounts payable associated with the DMT Study.
Read full article
Jun 07, 2022 08:30 ET
Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a definitive agreement (the "Agreement") dated June 7, 2022 with Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. ("Cybin"), pursuant to which the Company has agreed to sell its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to the Purchaser (the "Transaction") for a purchase price of CAD$1,000,000, a portion of which will be a deposit with the balance payable on closing of the Transaction. In connection with the Transaction, the Purchaser will assume all accrued liabilities and accounts payable associated with the DMT Study.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
2.10
--
--
Price to Sales - TTM
107.85
10.00
4.29
Price to Book - most recent quarter
0.71
2.37
1.79
Price to Cash Flow per share - TTM
--
9.90
8.07
Price to Free Cash Flow per share - TTM
--
29.88
18.98
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 31, 20226,627690
Jul 15, 20225,937-86,550
Jun 30, 202292,487-30,490
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Entheon Biomedical Corp. is a biotechnology research and development company. The Company focuses on developing a portfolio of Dimethyltryptamine (DMT) based psychedelic therapeutic products for treating addiction and substance use disorders. The Company's DMT is advancing and sustaining new models of psychedelic-assisted therapy. The Company is developing a combination of genetic and predictive data analysis to ensure the safest psychedelic treatment possible. The Company is also developing a predictive biomarker response platform in partnership with Divergence NeuroTech. Its biomarker platform is artificial intelligence and machine learning and prescribes suitable psychedelic treatments and provides real-time feedback during a psychedelic event, and informs the development of a post-therapy system of patient-specific support.

See business summary

 

Twitter

Search (past week) for $ENBI.CA

  • No tweets found